NKTX

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc. (NKTX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.8
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -45.7%
Price Return 12M -37.1%
Catalyst Signal 0.00
Market Cap $90.6M
TTM Revenue N/A
Price / Sales N/A
ROE -46.6%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (2.1) C- (2.0) D+ (1.8) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) D+ (1.7) C- (2.1) C- (2.0) C+ (2.7) C (2.2)
2026-10-30 C+ (2.5) D+ (1.7) C (2.3) C+ (2.6) C+ (2.7) C (2.3)
2026-10-23 C+ (2.5) D+ (1.7) C (2.3) C (2.4) C+ (2.6) C (2.3)
2026-10-16 C+ (2.5) D+ (1.7) C (2.3) C (2.5) C+ (2.6) C (2.3)
Page 1 of 4